<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175952</url>
  </required_header>
  <id_info>
    <org_study_id>16YFZCSY00800</org_study_id>
    <nct_id>NCT03175952</nct_id>
  </id_info>
  <brief_title>Virtual Histology Intravascular Ultrasound to Evaluate Prognostic Risks of Saphenous Vein Graft Disease Before Percutaneous Coronary Intervention.</brief_title>
  <official_title>Virtual Histology Intravascular Ultrasound to Evaluate Prognostic Risks of Saphenous Vein Graft Disease Before Percutaneous Coronary Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective cohort study conducted in Tianjin Chest Hospital, China. Patients
      with saphenous vein graft disease after coronary artery bypass graft, and planning for
      receiving percutaneous coronary intervention after virtual histology intravascular ultrasound
      will be enrolled between May 2017 and April 2019. These subjects will be followed up at 1, 6
      and 12 months post-operation of PCI to assess the short-term and long-term effect.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of major adverse cardiovascular events</measure>
    <time_frame>after PCI for saphenous vein graft disease (SVGD) in one year</time_frame>
    <description>Cardiac death, myocardial infarction, target lesion revascularization and target vessel revascularization are all major adverse cardiovascular events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis In Myocardial Infarction (TIMI) flow in 24 hours after PCI for the SVGD</measure>
    <time_frame>24 hours after PCI for the SVGD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of slow reflow, no reflow or distal embolization of the saphenous vein graft after PCI on the basis of Corrected TIMI Frame Count (TFC)</measure>
    <time_frame>24 hours after PCI for the SVGD</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of PCI</measure>
    <time_frame>24 hours after PCI for the SVGD</time_frame>
    <description>The residual stenosis of SVG is less than 50% and achieving TIMI flow 3</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Major Adverse Cardiovascular Events</condition>
  <condition>Saphenous Vein Graft Disease</condition>
  <condition>Virtual Histology Intravascular Ultrasound</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>PCI</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>virtual histology intravascular ultrasound</intervention_name>
    <description>Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.</description>
    <arm_group_label>PCI</arm_group_label>
    <other_name>percutaneous coronary intervention</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study is a prospective cohort study conducted in Tianjin Chest Hospital, China.
        Patients with SVGD after CABG, and planning for receiving PCI after VH-IVUS will be
        enrolled between April 2017 and March 2019. These subjects will be followed up at 1, 6 and
        12 months post-operation of PCI to assess the short-term and long-term effect.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SVGD after CABG

          -  Planning to receive PCI using drug-eluting stents

          -  18 to 80 years old

          -  Finishing VH-IVUS examination

          -  Willing to participate in the study and sign informed consent

        Exclusion Criteria:

          -  Patients with liver disfunction and renal failure

          -  Aspirin and clopidogrel allergy

          -  Acute myocardial infarction after CABG

          -  History of stroke in the past 3 months

          -  Gastrointestinal bleeding and hemoptysis recently

          -  Vasculitis and non-atherosclerotic coronary artery disease

          -  Coagulation disorders

          -  History of malignancy

          -  Women during pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yin Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Li, Ph.D.</last_name>
    <phone>0086-010-82805775-622</phone>
    <email>lixiang_pucri@bjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Gao, M.D.</last_name>
      <phone>0086-022-88185303</phone>
      <email>gaojing2088@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Chest Hospital</investigator_affiliation>
    <investigator_full_name>Yin Liu</investigator_full_name>
    <investigator_title>director, Cardiology Department</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

